| (Values in U.S. Thousands) | Dec, 2021 | Dec, 2020 | Dec, 2019 | Dec, 2018 | Dec, 2017 |
| Sales | 47,790 | 29,630 | 40,520 | 13,980 | 0 |
| Sales Growth | +61.29% | -26.88% | +189.84% | unch | -100.00% |
| Net Income | 3,010 | -1,860 | 11,590 | -21,200 | 0 |
| Net Income Growth | +261.83% | -116.05% | +154.67% | unch | -100.00% |
Opiant Pharmaceuticals Inc (OPNT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Opiant Pharmaceuticals, Inc. is a specialty pharmaceutical company. It is engaged in developing opioid antagonist treatments for substance use, addictive and eating disorders. Opiant Pharmaceuticals Inc., formerly known as Lightlake Therapeutics, Inc., is based in New York.
Fiscal Year End Date: 12/31